New York State Teachers Retirement System Purchases 200 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

New York State Teachers Retirement System raised its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 0.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,380 shares of the specialty pharmaceutical company’s stock after acquiring an additional 200 shares during the period. New York State Teachers Retirement System owned approximately 0.11% of ANI Pharmaceuticals worth $1,234,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. lifted its holdings in shares of ANI Pharmaceuticals by 93.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 248 shares during the last quarter. BluePath Capital Management LLC acquired a new position in ANI Pharmaceuticals during the 3rd quarter valued at about $34,000. Pacer Advisors Inc. purchased a new stake in ANI Pharmaceuticals in the fourth quarter valued at about $41,000. Point72 Asset Management L.P. boosted its holdings in ANI Pharmaceuticals by 60.0% in the second quarter. Point72 Asset Management L.P. now owns 776 shares of the specialty pharmaceutical company’s stock worth $42,000 after acquiring an additional 291 shares in the last quarter. Finally, Coppell Advisory Solutions LLC purchased a new stake in shares of ANI Pharmaceuticals during the second quarter worth about $44,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at ANI Pharmaceuticals

In related news, COO Muthusamy Shanmugam sold 5,692 shares of ANI Pharmaceuticals stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $55.95, for a total value of $318,467.40. Following the sale, the chief operating officer now owns 897,620 shares of the company’s stock, valued at approximately $50,221,839. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, COO Muthusamy Shanmugam sold 5,692 shares of the company’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $55.95, for a total transaction of $318,467.40. Following the completion of the transaction, the chief operating officer now owns 897,620 shares in the company, valued at approximately $50,221,839. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Stephen P. Carey sold 7,787 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $65.55, for a total transaction of $510,437.85. Following the completion of the transaction, the chief financial officer now directly owns 177,712 shares in the company, valued at $11,649,021.60. The disclosure for this sale can be found here. Insiders sold a total of 145,686 shares of company stock valued at $9,586,490 in the last three months. 12.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Capital One Financial initiated coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 15th. They issued an “overweight” rating and a $80.00 target price for the company. HC Wainwright lifted their price objective on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a research note on Monday, March 4th. Truist Financial upped their target price on ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, Guggenheim lifted their price target on ANI Pharmaceuticals from $70.00 to $77.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $80.00.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP opened at $65.48 on Thursday. The company has a 50 day simple moving average of $64.60 and a two-hundred day simple moving average of $58.52. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of 77.95 and a beta of 0.79. The company has a current ratio of 3.57, a quick ratio of 2.81 and a debt-to-equity ratio of 0.66. ANI Pharmaceuticals, Inc. has a 12 month low of $36.99 and a 12 month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $131.65 million for the quarter, compared to the consensus estimate of $123.02 million. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. As a group, analysts predict that ANI Pharmaceuticals, Inc. will post 3.55 earnings per share for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.